Advancing Drug Safety: The Synergy Of Regulatory Affairs And Pharmacovigilance

By Robert Martini and Victoria Rogers

In the pharmaceutical industry, regulatory affairs (RA) and pharmacovigilance (PV) are often viewed as separate entities with distinct responsibilities. RA navigates the complex landscape of drug approval, while PV monitors a drug's safety once it reaches the market. However, this siloed perception overlooks a critical reality: their collaboration is not just beneficial, but essential for safeguarding public health. From pre-approval planning to post-market surveillance, the synergy between these two functions ensures that medicines are both effective and safe for patient use. This dynamic partnership is fundamental to identifying, analyzing, and mitigating potential risks throughout a medication’s lifecycle.

Learn more about how this vital collaboration works in practice by reading the full article.